Findings from a large, multi-cohort study suggest the genomic test can improve care for lung nodule patients with inconclusive bronchoscopy results
SOUTH SAN FRANCISCO, Calif., July 13, 2022--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data published today in PLOS O
July 20, 2022 -- Lung cancer patients with inconclusive bronchoscopy results have just received encouraging news that their tests can now be more accurately classified for cancer risk.
In a study published in the journal PLOS One, a group of researchers has clinically confirmed that Ver
July 20, 2022 -- Lung cancer patients with inconclusive bronchoscopy results have just received encouraging news that their tests can now be more accurately classified for cancer risk.
In a study published in the journal PLOS One, a group of researchers has clinically confirmed that Ver
"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
Some passing clouds. A stray afternoon thunderstorm is possible. Low 71F. Winds SSW at 5 to 10 mph..
Some passing clouds. A stray afternoon thunderstorm is possible. Low 71F. Winds SSW at 5 to 10 mph.
From left, PTC Paramedic Instructor Steve McDad
Washington [US], July 6 (ANI): Swallowing fluoroscopy is the most common diagnostic test for patients with swallowing problems caused by conditions such as stroke, head and neck cancer, neurodegenerative diseases, or prolonged intubation. In spite of its widespread use, there wasn’t any
Washington [US], July 6 (ANI): Swallowing fluoroscopy is the most common diagnostic test for patients with swallowing problems caused by conditions such as stroke, head and neck cancer, neurodegenerative diseases, or prolonged intubation. In spite of its widespread use, there wasn’t any
"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.